安徽宏宇五洲医疗器械股份有限公司 独立董事 2023 年度述职报告 安徽宏宇五洲医疗器械股份有限公司董事会 二〇二三年四月十五日 | 独立董事 2023 年度述职报告目录 1 | | --- | | 王清刚 2 | | 娄亦捷 9 | | 郑晓风 15 | | 顾光（离任） 21 | | 李玉文（离任） 28 | 独立董事 2023 年度述职报告 安徽宏宇五洲医疗器械股份有限公司 安徽宏宇五洲医疗器械股份有限公司 独立董事 2023 年度述职报告 王清刚 尊敬的各位股东及股东授权代表： 本人作为安徽宏宇五洲医疗器械股份有限公司（以下简称"公司"） 独立董事，根据《公司法》《上市公司治理准则》《深圳证券交易所创 业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号 ——创业板上市公司规范运作》等法律法规及《公司章程》《公司独 立董事制度》等要求，忠实、勤勉、独立履行独立董事职责，积极出 席相关会议，认真审议董事会各项议案，监督公司规范运作情况，充 分发挥独立董事的作用，切实维护公司和全体股东利益，特别是中小 股东的合法权益。现将本人 2023 年度履行公司独立董事职责情况汇 报如下： 一、独立董事的 ...

Shareholder Structure - The total number of ordinary shareholders at the end of the reporting period was 8,562[5] - Huang Fan holds 24.16% of the shares, totaling 16,429,650 shares[5] - Xiang Bingyi holds 20.25% of the shares, totaling 13,770,000 shares[5] - Zhang Hongyu holds 9.00% of the shares, totaling 6,120,000 shares[5] - Zou Aiying holds 6.00% of the shares, totaling 4,080,000 shares[5] - Taihu Honghui Medical Management Partnership holds 5.24% of the shares, totaling 3,562,350 shares[5] - Zhang Liang holds 3.75% of the shares, totaling 2,550,000 shares[5] - Chen Xiaoru holds 2.25% of the shares, totaling 1,530,000 shares[5] - Liu Yueye holds 0.75% of the shares, totaling 510,000 shares[5] - Zhou Lexiang holds 0.75% of the shares, totaling 510,000 shares[5] Financial Performance - The company's non-recurring gains and losses for 2023 amounted to RMB 5,229,662.99, a decrease from RMB 9,071,340.43 in 2022[26] - Government subsidies included in current profits for 2023 were RMB 4,750,864.76, significantly lower than RMB 19,093,425.33 in 2022[26] - Revenue for 2023 was 533.68 million yuan, a decrease of 2.46% compared to 547.11 million yuan in 2022[82] - Net profit attributable to shareholders in 2023 was 60.27 million yuan, a decrease of 15.04% compared to 70.93 million yuan in 2022[82] - Revenue from syringe products decreased by 4.04% to 218.88 million yuan, accounting for 41.01% of total revenue[84] - Revenue from medical puncture needles decreased by 18.37% to 155.25 million yuan, accounting for 29.09% of total revenue[84] - Revenue from infusion and transfusion sets increased by 18.33% to 92.77 million yuan, accounting for 17.38% of total revenue[84] - Overseas revenue accounted for 97.42% of total revenue, amounting to 519.93 million yuan, a decrease of 2.09% year-on-year[84] - Total revenue for 2023 was RMB 533.68 million, a decrease of 2.46% compared to RMB 547.11 million in 2022[108] - Net profit for 2023 was RMB 60.27 million, a decrease of 15.03% compared to RMB 70.93 million in 2022[109] - R&D expenses for 2023 were RMB 13.48 million, an increase of 2.96% compared to RMB 13.09 million in 2022[108] - Total revenue for 2023 was 389,815,623.68 yuan, a decrease from 415,280,783.39 yuan in 2022[125] - Operating costs for 2023 were 300,813,193.41 yuan, down from 318,151,631.78 yuan in 2022[125] - R&D expenses for 2023 increased to 13,478,535.30 yuan from 13,091,362.65 yuan in 2022[125] - Net cash flow from operating activities in 2023 was 271,319,873.54 yuan, up from 104,165,392.23 yuan in 2022[118] - Total assets as of December 31, 2023, were 848,178,419.23 yuan, compared to 844,597,231.04 yuan at the beginning of the year[118] - Fixed assets increased significantly to 304,661,292.44 yuan in 2023 from 169,364,723.51 yuan in 2022[118] - Total liabilities decreased to 98,470,621.61 yuan in 2023 from 121,154,488.86 yuan in 2022[120] - Net profit attributable to the parent company in 2023 was 258,604,782.29 yuan, up from 237,065,810.34 yuan in 2022[120] - The company's financial expenses in 2023 were -5,099,986.02 yuan, compared to -4,423,214.67 yuan in 2022[125] - The company's total equity as of December 31, 2023, was 749,707,797.62 yuan, up from 723,442,742.18 yuan at the beginning of the year[120] - The company's R&D investment in 2023 was RMB 13,478,535.30, accounting for 2.53% of the operating revenue, an increase from 2.39% in 2022[132] Industry and Market Overview - The company operates in the medical device manufacturing industry, specifically focusing on disposable sterile infusion medical consumables, with sales networks covering over 80 countries and regions[28] - The company has established a comprehensive technological R&D and quality assurance system, with international customer resource advantages[28] - The Chinese government issued 4 new policies and regulations affecting the medical device industry in 2023, including the "Medical Device Emergency Use Management Regulations (Trial)" and the "High-Quality Development Action Plan for the Pharmaceutical Industry (2023-2025)"[29] - The EU revised MDR and IVDR regulations in March 2023 to address medical device shortages[36] - The US FDA released an updated 510(k) program plan in September 2023 to strengthen premarket notification procedures and encourage innovative technologies[37] - The medical consumables industry has reached a mature stage, with stable global demand growth and China's competitive advantage in manufacturing[28] - The company's main business is the R&D, manufacturing, and sales of disposable sterile infusion medical devices, with a focus on the "ODM + integrated supply" model to meet the one-stop procurement needs of international medical device brand owners[38] - The company's main products include syringes, infusion and transfusion sets, medical puncture needles, and other diagnostic and clinical care products, covering a wide range of medical applications[40] - The company's sales model is primarily export-oriented, with domestic sales as a supplement, and it collaborates with international medical device brand owners through ODM[41] - The company's 2023 annual revenue was RMB 533,679,925.02, primarily from the R&D, production, and sales of medical puncture devices, including syringes, infusion and transfusion sets, and puncture needles[63] - The company's products are sold in over 80 countries and regions across Asia, Europe, and the Americas, with a stable customer base of over 300 clients[48] - The company has established a competitive advantage in the disposable sterile infusion medical device segment through continuous innovation, quality improvement, and optimized production processes[49] - The company's internal performance drivers include a well-established R&D and quality assurance system, while external drivers include global economic growth, population aging, and increasing demand for medical consumables[42] - The global medical consumables industry is in a mature stage, with stable growth in demand, particularly in developing countries due to improved healthcare conditions[46] - The company has a strong reputation in the traditional infusion product market, supported by automated production equipment, mature production processes, and a robust quality control system[48] - The company operates in over 80 countries and regions across Asia, Europe, and the Americas, primarily through an "ODM + integrated supply" model to meet the one-stop procurement needs of international medical device brands[198] R&D and Innovation - The company obtained 12 utility model patents and 2 design patents in 2023, and 3 products received FDA approval[83] - As of the end of 2023, the company held 92 patents, including 1 invention patent, 77 utility model patents, and 14 design patents[83] - The company completed product design development and registration for multiple new products, including safety infusion needles and self-destruct syringes[97] - The company is in the design conversion and verification phase for several new products, such as central venous catheters and PICC lines[97] - The company terminated the development of disposable dental needles[97] - The company is focusing on expanding its product line and enhancing product competitiveness through new product development[97] - The company obtained 3 FDA product registrations in 2023, bringing the total number of medical device registrations and certifications to 47, including 11 domestic registrations, 16 CE certifications, and 20 FDA registrations[135] - The company is developing a fully automatic rebound blood collection needle, which is in the registration stage and aims to enhance product competitiveness[131] - The company is in the design input phase for an automatic rebound insulin safety injection needle, which is expected to expand the product line and improve competitiveness[131] - The company is developing a safety protection needle for disposable drug delivery devices, which is in the design input phase and aims to expand the product line[131] - The company is in the pilot verification stage for an improved precision syringe with additional support, which is expected to add product functionality and expand the product line[131] - The company is developing a safety protection needle for venous blood collection, which is in the design conversion and verification phase and aims to expand the product line[131] - The company is implementing intelligent transformation in medical device production and material delivery processes, which is expected to reduce labor costs and improve product quality[131] - The company is in the design conversion and verification phase for a universal injection needle with safety protection, which aims to expand the product line[131] - The company has established a research and development system that matches its business needs, with a mechanism for human resource reserve, training, and introduction, ensuring no significant adverse impact on core competitiveness[134] Quality Control and Compliance - The company's accounts receivable recoverability was identified as a key audit matter, with specific procedures implemented to assess the reasonableness of assumptions and estimates[24] - The company reported no differences in net profit and net assets between Chinese and international accounting standards[25] - The company has established a comprehensive quality control system in compliance with international standards, including EU MDD and US FDA QSR 820 regulations[185] - The company has 16 types of sterile disposable medical devices registered in China, all classified as Class IIa, with certificates valid until December 31, 2028[138] - The company has 13 types of medical devices registered with the FDA, including Class I and Class II devices, with some registrations dating back to 2021[140] - The company's FDA-registered devices include insulin syringes, blood collection sets, and safety hypodermic needles, with some registrations as recent as April 12, 2022[140] - The company's sterile disposable devices in China include insulin syringes, blood transfusion sets, and dental injection needles, all with a 5-year validity period[138] - The company's FDA-registered devices include dental irrigation syringes and vacuum blood collection sets, with some registrations dating back to 2021[140] - The company's sterile disposable devices in China include precision flow regulators and safety blood collection needles, all with a 5-year validity period[138] - The company's FDA-registered devices include safety hypodermic needles with syringes, with registrations dating back to October 4, 2021[140] - The company's sterile disposable devices in China include intravenous needles and infusion sets, all with a 5-year validity period[138] - The company's FDA-registered devices include insulin pen needles and blood collection needle holders, with some registrations dating back to 2021[140] - The company's sterile disposable devices in China include sterile dental injection needles and safety hypodermic needles, all with a 5-year validity period[138] Operational Efficiency and Costs - Sales volume decreased by 21.26% to 575,737.63 thousand units in 2023 compared to 731,170.38 thousand units in 2022[88] - Production volume decreased by 23.47% to 564,814.82 thousand units in 2023 compared to 738,006.08 thousand units in 2022[88] - Inventory volume decreased by 19.11% to 46,227.84 thousand units in 2023 compared to 57,150.65 thousand units in 2022[88] - Direct material costs decreased by 3.94% to 293,112,050.18 yuan, accounting for 69.80% of total operating costs in 2023[90] - Manufacturing expenses increased by 19.60% to 63,370,694.80 yuan, accounting for 15.09% of total operating costs in 2023[90] - Top 5 customers accounted for 29.02% of total annual sales, with total sales of 154,918,858.61 yuan in 2023[92] - Top 5 suppliers accounted for 32.62% of total annual purchases, with total purchases of 122,902,131.75 yuan in 2023[92] - Sales expenses increased by 17.06% to 15,305,821.92 yuan in 2023 compared to 13,075,299.05 yuan in 2022[94] - Management expenses decreased by 34.03% to 19,946,827.57 yuan in 2023 compared to 30,237,924.18 yuan in 2022[94] - R&D expenses increased by 2.96% to 13,478,535.30 yuan in 2023 compared to 13,091,362.65 yuan in 2022[94] - The number of R&D personnel decreased by 5.00% to 95 in 2023 from 100 in 2022[99] - The proportion of R&D personnel with a bachelor's degree decreased by 12.50% to 14 in 2023 from 16 in 2022[99] - The company's financial expenses decreased to RMB -8.02 million in 2023 from RMB -7.86 million in 2022, primarily due to increased interest income[108] - The company has achieved automated production in key processes such as feeding, injection molding, and sterilization, improving production efficiency and reducing costs[78] Strategic Plans and Risks - The company plans to focus on four key areas in 2024: implementation of fundraising projects, R&D of new technologies and products, promotion of lean manufacturing, and development of customer and market systems[177] - The company faces risks such as intensified market competition, fluctuations in raw material prices, quality control issues, high reliance on export revenue, and exchange rate risks[183][184][185][186][187] - The company aims to improve its competitiveness by developing new technologies and products, enhancing product quality, and optimizing manufacturing costs[183] - To mitigate raw material price risks, the company will monitor market trends and adjust procurement strategies accordingly[184] - To reduce reliance on export revenue, the company plans to increase domestic market share and gradually raise the proportion of domestic sales[186] - The company will use forward exchange contracts to hedge against potential losses caused by RMB exchange rate fluctuations[187] - The company has not identified any issues affecting its ability to continue operations for the next 12 months, and it is reasonable to prepare financial statements on a going concern basis[200] Subsidiaries and Investments - Anhui Hongyu Wuzhou Import and Export Co., Ltd., established in September 2016, is a subsidiary primarily engaged in the export of medical devices, forming part of the company's main business[148] - The company's subsidiary, Anhui Hongyu Wuzhou Import & Export Co., Ltd., reported total assets of 129,918,558.17 yuan, net assets of 93,951,647.62 yuan, and operating revenue of 321,287,831.72 yuan[178] - The company's over-raised funds amount to 62.54 million yuan, with 18 million yuan permanently supplementing working capital and 44.54 million yuan used for the "Disposable Infusion Puncture Medical Device Technical Transformation and Expansion Project"[145] - As of December 31, 2023, the company has used 33.12 million yuan of over-raised funds for the "Disposable Infusion Puncture Medical Device Technical Transformation and Expansion Project"[145] - The company has pre-invested 143.87 million yuan in fundraising projects and 10.07 million yuan in issuance fees, with a total of 153.94 million yuan replaced by raised funds[145] - Unused raised funds include 22.90 million yuan in special fundraising accounts and 25 million yuan in cash management[146] - The company's total equity at the end of the previous year was 262,769,800.56 yuan, with a capital reserve of 22,510,275.27 yuan and undistributed profits of 171,768,569.20 yuan[163] - During the current period, the company increased its capital by 17,000,000.00 yuan and raised additional capital of 372,742,391.76 yuan, resulting in a total increase in equity of 389,742,391.76 yuan[164] - The company's comprehensive income for the period was 70,930,549.86 yuan, contributing to the overall increase in equity[164] - The company's total equity at the beginning of the current year was 652,495,315.10 yuan, with a capital reserve of 395,252,667.03 yuan and undistributed profits of 166,118,383.26 yuan[165] - The company's comprehensive income for the current year was 47,260,834.90 yuan, contributing to the overall increase in equity[165] - The company's total owner's equity at the end of the period was 652,495,315.10 yuan, with a capital reserve of 395,252,667.03 yuan and retained earnings of 166,118,383.26 yuan[169] Market and Customer Relationships - The company has established stable cooperative relationships with well-known medical device brand companies in over 80 countries and regions[76] - The company's total share capital is 51 million shares, with Huang Fan holding the largest share at 1,642,970 shares, representing 32.22% of the total[196]

证券代码：301234 证券简称：五洲医疗 公告编号：2024-018 安徽宏宇五洲医疗器械股份有限公司 关于续聘 2024 年度审计机构的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或者重大遗漏。 安徽宏宇五洲医疗器械股份有限公司（以下简称"公司"）于 2024 年 4 月 15 日召开第三届董事会第二次会议和第三届监事会第二次会议，会议审议通过了 《关于续聘 2024 年度审计机构的议案》。公司拟续聘容诚会计师事务所（特殊普 通合伙）（以下简称"容诚会计师事务所"）为 2024 年度审计机构，本议案尚需 提交公司 2023 年年度股东大会审议。现将有关情况公告如下： 一、拟续聘会计师事务所事项的情况说明 容诚会计师事务所依法独立承办注册会计师业务，具备证券期货相关业务审 计从业资格，具有上市公司审计工作的丰富经验和职业素养。其在担任公司审计 机构期间，遵循《中国注册会计师独立审计准则》等相关规定，勤勉尽责，坚持 独立、客观、公正的审计准则，公允合理地发表了审计意见。 为保持审计工作的连续性，公司董事会同意继续聘请容诚会计师事务所为公 司 2024 年度审计机构 ...

2024 年，公司预计向关联企业贝普医疗科技股份有限公司及其关联方（以 下简称"贝普医疗"）采购原材料产品组件和产品不超过 700.00 万元，销售产品 或商品不超过 700.00 万元；预计向关联自然人项炳义、邹爱英、杨林（以下简称 "关联自然人"）租赁办公场所固定资产租赁费不超过 25.00 万元。 光大证券股份有限公司关于安徽宏宇五洲医疗器械股份有 限公司 2024 年度日常关联交易预计的核查意见 光大证券股份有限公司（以下简称"光大证券"、"保荐机构"）作为安徽宏宇 五洲医疗器械股份有限公司（以下简称"五洲医疗"或者"公司"）首次公开发行股 票并在创业板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳 证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等相关法律、法规和规范性文件的规定，对公 司 2024 年度日常关联交易预计事项进行了审慎核查，核查情况如下： 一、 日常关联交易基本情况 （一）日常关联交易情况概述 2023 年，公司与关联方日常关联交易总额 214.33 万元，其中：公司向贝普 医疗采购医用采血针产品 193.63 万元 ...

【RsM】容 诚 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://a.co.nof.gov.cn）" 进行变 上一 目 录 | 序号 | 内 容 | 页码 | | --- | --- | --- | | 1 | 募集资金年度存放与使用情况鉴证报告 | 1-2 | | 2 | 募集资金年度存放与使用情况专项报告 | 3-7 | 容诚专字[2024]230Z1310 号 容诚会计师事务所 (特殊普通合伙) 募集资金年度存放与使用情况鉴证报告 安徽宏宇五洲医疗器械股份有限公司 中国·北京 募集资金年度存放与使用情况鉴证报告TEL: 01 容诚专字[2024]230Z1310 号 安徽宏宇五洲医疗器械股份有限公司全体股东: 我们审核了后附的安徽宏宇五洲医疗器械股份有限公司（以下简称五洲医疗） 董事会编制的 2023 年度《关于募集资金年度存放与使用情况的专项报告》。 一、对报告使用者和使用目的的限定 本鉴证报告仅供五洲医疗年度报告披露之目的使用,不得用作任何其他目的。 我们同意将本鉴证报告作为五洲医疗年度报告必备的文件,随其他文件一起报送 并对外披露。 二、董事会的责任 按照中国证券监督管理委 ...

按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效 性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建立和实施 内部控制进行监督。经理层负责组织领导企业内部控制的日常运行。公司董事会、监事 会及董事、监事、高级管理人员保证本报告内容不存在任何虚假记载、误导性陈述或重 大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关 信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局 限性，故仅能为实现上述目标提供合理保证。此外，由于情况的变化可能导致内部控制 变得不恰当，或对控制政策和程序遵循的程度降低，根据内部控制评价结果推测未来 内部控制的有效性具有一定的风险。 二、内部控制评价结论 2023 年度内部控制自我评价报告 安徽宏宇五洲医疗器械股份有限公司 安徽宏宇五洲医疗器械股份有限公司 2023 年度内部控制自我评价报告 安徽宏宇五洲医疗器械股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以 下简称"企业内部控制规范体系"） ...

Financial Performance - The total operating revenue for Q1 2024 was ¥90,040,221.08, a decrease of 23.2% compared to ¥117,355,998.88 in the same period last year[21]. - The total operating costs for Q1 2024 were ¥80,849,921.31, down 22.4% from ¥104,154,087.68 in Q1 2023[21]. - Net profit attributable to shareholders is ¥9,884,675.60, down 23.77% year-over-year[37]. - Net profit for the first quarter was 9,884,675.60, a decrease of 23.99% compared to 12,967,646.49 in the previous year[60]. - Operating profit for the quarter was 11,957,062.17, down from 15,590,525.82 in the previous year[60]. - Basic and diluted earnings per share were both 0.1454, compared to 0.1907 in the previous year, reflecting a decline in profitability[60]. - Total comprehensive income for the quarter was 9,884,675.60, a decrease from 12,967,646.49 in the previous year[60]. Cash Flow - The net cash flow from investment activities was 9,434,158.18 CNY, compared to 148,318,107.39 CNY in the previous period, indicating a significant decrease[6]. - The cash flow from operating activities was not detailed, but the overall cash position improved significantly during the quarter[6]. - The net cash flow from operating activities for Q1 2024 was ¥32,844,785.29, significantly up from ¥14,944,036.17 in Q1 2023, representing a 119.5% increase[18]. - The company's cash and cash equivalents at the end of Q1 2024 were ¥314,533,444.66, an increase of 15.9% from ¥271,319,873.54 at the beginning of the period[15]. - The company's cash and cash equivalents decreased significantly, impacting liquidity and operational flexibility[39]. - The company recorded a significant decrease of 93.64% in net cash flow from investing activities, totaling ¥9,434,158.18, due to reduced purchases and redemptions of financial products[41]. Shareholder Information - The company reported a total of 8,141 common shareholders at the end of the reporting period[12]. - The largest shareholder, Huang Fan, holds 24.16% of the shares, amounting to 13,770,000 shares[12]. - The total equity attributable to shareholders increased to ¥759,592,473.22 from ¥749,707,797.62, showing a growth of 1.2%[21]. - The total equity attributable to shareholders increased by 1.32% to ¥759,592,473.22 at the end of the current period[37]. Investment Activities - The cash inflow from investment activities was ¥125,372,587.18, down 64.3% from ¥351,356,583.24 in the same period last year[18]. - The cash outflow from investment activities totaled 115,938,429.00 CNY, compared to 203,038,475.85 CNY in the previous period, showing a decrease in investment spending[6]. - The cash outflow for purchasing fixed assets and intangible assets was ¥13,938,429.00, a decrease of 56.3% compared to ¥31,862,535.85 in Q1 2023[18]. Liabilities and Assets - The total liabilities decreased to ¥74,028,058.80 from ¥98,470,621.61, indicating a reduction of 25.0%[21]. - The total assets at the end of the current period are ¥833,620,532.02, reflecting a decrease of 1.72% from the end of the previous year[37]. - The accounts receivable decreased to ¥67,273,730.47 from ¥92,696,934.48, reflecting a reduction of 27.5%[15]. Other Income and Expenses - Financial expenses decreased significantly by 283.48%, from 1,577,924.57 to -2,895,152.53, mainly due to increased exchange gains and interest income[53]. - Other income increased by 154.62%, from 899,793.96 to 2,291,047.37, primarily due to higher government subsidies received[53]. - Investment income dropped by 84.96%, from 2,072,546.21 to 311,723.18, mainly due to reduced returns from financial products[53]. - The company reported a significant increase in credit impairment losses by 63.65%, from 943,098.18 to 1,543,400.01, attributed to a decrease in bad debt provisions[53]. Government Subsidies - The company received government subsidies amounting to ¥1,944,750.00 during the current period[38]. Non-Recurring Gains and Losses - The company adjusted its non-recurring gains and losses for the first quarter of 2023, increasing the net amount by 275,174.42 CNY after tax[10]. - The company did not report any non-recurring gains or losses during the quarter[51]. Audit and Adjustments - The first quarter report was not audited, and there were no adjustments or restatements of prior year accounting data[49][50].

光大证券股份有限公司关于安徽宏宇五洲医疗器械股份有限公 司 2023 年度内部控制自我评价报告的核查意见 光大证券股份有限公司（以下简称"光大证券"或"保荐机构"）作为安徽宏宇五洲 医疗器械股份有限公司（以下简称"五洲医疗"、"公司"）的保荐机构，根据《证券发 行上市保荐业务管理办法》、《深圳证券交易所创业板股票上市规则》、《深圳证券交易 所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等相关法律法规文件要求， 对五洲医疗《2023 年度内部控制自我评价报告》进行审慎核查，发表如下意见： 一、公司内部控制评价工作情况 （一）内部控制评价的范围 公司围绕内部环境、风险评估、控制活动、信息与沟通、内部监督等要素，按照风险 导向原则确定纳入评价范围的主要单位、业务和事项以及高风险领域。 纳入评价范围的主要单位包括公司及合并报表范围内的子公司：具体包括安徽宏宇五 洲医疗器械股份有限公司、安徽宏宇五洲进出口有限公司。纳入评价范围单位资产总额占 公司合并财务报表资产总额的 100%，营业收入合计占公司合并财务报表营业收入总额的 100%。 纳入评价范围的主要业务和事项包括：治理结构、组织机构、内部审计机构、人 ...

一、日常关联交易基本情况 1、日常关联交易概述 证券代码：301234 证券简称：五洲医疗 公告编号：2024-011 安徽宏宇五洲医疗器械股份有限公司 关于 2024 年度日常关联交易预计的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或者重大遗漏。 公司 2023 年度日常关联交易根据股东大会授权开展，符合法律、行政法规 和公司股东大会决议的规定。公司根据 2023 年度日常关联交易执行情况，结合 2024 年经营计划对 2024 年度日常关联交易进行预计，具体情况报告如下： 2024 年，公司预计向关联企业贝普医疗科技股份有限公司及其关联方（以 下简称"贝普医疗"）采购原材料产品组件和产品不超过 700.00 万元，销售产品 或商品不超过 700.00 万元；预计向关联自然人项炳义、邹爱英、杨林（以下简 称"关联自然人"）租赁办公场所固定资产租赁费不超过 25.00 万元。 2023 年，公司与关联方日常关联交易总额 214.33 万元，其中：公司向贝普 医疗采购医用采血针产品 193.63 万元，销售产品 0.00 万元；向关联自然人租赁 办公场所租赁费 2 ...

安徽宏宇五洲医疗器械股份有限公司 董事会审计委员会 2023 年度对会计师事务所履职情况 评估及履行监督职责情况的报告 安徽宏宇五洲医疗器械股份有限公司（以下简称"公司"）董事 会审计委员会根据《中华人民共和国公司法》《中华人民共和国证券 法》《上市公司治理准则》《国有企业、上市公司选聘会计师事务所管 理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》等法律法规、规范性文件以及《公司章程》《董 事会审计委员会工作规则》等规定和要求，本着勤勉尽责原则，恪尽 职守，认真履职。现将董事会审计委员会对会计师事务所 2023 年度 履职情况评估及履行监督职责的情况汇报如下： 一、2023 年度会计师事务所基本情况 容诚会计师事务所（特殊普通合伙）（以下简称"容诚会计师事 务所"）由原华普天健会计师事务所（特殊普通合伙）更名而来，初 始成立于 1988 年 8 月，2013 年 12 月 10 日改制为特殊普通合伙企 业，是国内最早获准从事证券服务业务的会计师事务所之一，长期从 事证券服务业务。注册地址为北京市西城区阜成门外大街 22 号 1 幢 外经贸大厦 901-22 至 901-2 ...